BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 25589648)

  • 1. Postchallenge administration of brincidofovir protects healthy and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus.
    Zaitseva M; McCullough KT; Cruz S; Thomas A; Diaz CG; Keilholz L; Grossi IM; Trost LC; Golding H
    J Virol; 2015 Mar; 89(6):3295-307. PubMed ID: 25589648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of postchallenge administration of ST-246 on dissemination of IHD-J-Luc vaccinia virus in normal mice and in immune-deficient mice reconstituted with T cells.
    Zaitseva M; Shotwell E; Scott J; Cruz S; King LR; Manischewitz J; Diaz CG; Jordan RA; Grosenbach DW; Golding H
    J Virol; 2013 May; 87(10):5564-76. PubMed ID: 23468500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an animal model of progressive vaccinia in nu/nu mice and the use of bioluminescence imaging for assessment of the efficacy of monoclonal antibodies against vaccinial B5 and L1 proteins.
    Zaitseva M; Thomas A; Meseda CA; Cheung CYK; Diaz CG; Xiang Y; Crotty S; Golding H
    Antiviral Res; 2017 Aug; 144():8-20. PubMed ID: 28495463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of delayed brincidofovir treatment against a lethal rabbitpox virus challenge in New Zealand White rabbits.
    Grossi IM; Foster SA; Gainey MR; Krile RT; Dunn JA; Brundage T; Khouri JM
    Antiviral Res; 2017 Jul; 143():278-286. PubMed ID: 28392420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organs.
    Zaitseva M; Kapnick SM; Meseda CA; Shotwell E; King LR; Manischewitz J; Scott J; Kodihalli S; Merchlinsky M; Nielsen H; Lantto J; Weir JP; Golding H
    J Virol; 2011 Sep; 85(17):9147-58. PubMed ID: 21715493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurements of vaccinia virus dissemination using whole body imaging: approaches for predicting of lethality in challenge models and testing of vaccines and antiviral treatments.
    Zaitseva M; Kapnick S; Golding H
    Methods Mol Biol; 2012; 890():161-76. PubMed ID: 22688767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus.
    Parker S; Crump R; Foster S; Hartzler H; Hembrador E; Lanier ER; Painter G; Schriewer J; Trost LC; Buller RM
    Antiviral Res; 2014 Nov; 111():42-52. PubMed ID: 25128688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: a model of smallpox disease.
    Trost LC; Rose ML; Khouri J; Keilholz L; Long J; Godin SJ; Foster SA
    Antiviral Res; 2015 May; 117():115-21. PubMed ID: 25746331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir.
    Smee DF; Bailey KW; Sidwell RW
    Antivir Chem Chemother; 2001 Jan; 12(1):71-6. PubMed ID: 11437324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice.
    Smee DF; Wong MH; Bailey KW; Beadle JR; Hostetler KY; Sidwell RW
    Int J Antimicrob Agents; 2004 May; 23(5):430-7. PubMed ID: 15120719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events post smallpox-vaccination: insights from tail scarification infection in mice with Vaccinia virus.
    Mota BE; Gallardo-Romero N; Trindade G; Keckler MS; Karem K; Carroll D; Campos MA; Vieira LQ; da Fonseca FG; Ferreira PC; Bonjardim CA; Damon IK; Kroon EG
    PLoS One; 2011 Apr; 6(4):e18924. PubMed ID: 21526210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice.
    Smee DF; Bailey KW; Wong MH; Sidwell RW
    Antiviral Res; 2001 Oct; 52(1):55-62. PubMed ID: 11530188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype.
    Kornbluth RS; Smee DF; Sidwell RW; Snarsky V; Evans DH; Hostetler KY
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4038-43. PubMed ID: 16982794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of cidofovir in a murine model of disseminated progressive vaccinia.
    Neyts J; Leyssen P; Verbeken E; De Clercq E
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2267-73. PubMed ID: 15155231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease.
    Israely T; Paran N; Lustig S; Erez N; Politi B; Shafferman A; Melamed S
    Virol J; 2012 Jun; 9():119. PubMed ID: 22709563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of N-methanocarbathymidine in treating mice infected intranasally with the IHD and WR strains of vaccinia virus.
    Smee DF; Hurst BL; Wong MH; Glazer RI; Rahman A; Sidwell RW
    Antiviral Res; 2007 Nov; 76(2):124-9. PubMed ID: 17658623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buccal viral DNA as a trigger for brincidofovir therapy in the mousepox model of smallpox.
    Crump R; Korom M; Buller RM; Parker S
    Antiviral Res; 2017 Mar; 139():112-116. PubMed ID: 28039021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice.
    Neyts J; De Clercq E
    J Med Virol; 1993 Nov; 41(3):242-6. PubMed ID: 8263505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insufficient Innate Immunity Contributes to the Susceptibility of the Castaneous Mouse to Orthopoxvirus Infection.
    Earl PL; Americo JL; Moss B
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical treatment of cutaneous vaccinia virus infections in immunosuppressed hairless mice with selected antiviral substances.
    Smee DF; Bailey KW; Wong MH; Tarbet EB
    Antivir Chem Chemother; 2011 May; 21(5):201-8. PubMed ID: 21566266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.